Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 114 of the 117 references it cites were found in a registry or an index; 25 of the 152 sources its claims cite were checked for support.

The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities

Open access

Abstract

Purpose of Review: This review examines lifestyle modification for obesity management with the goal of identifying treatment components that could support the use of a new generation of anti-obesity medications (AOMs). Recent Findings: Semaglutide reliably reduces baseline body weight by approximately 15% at 68 weeks, in contrast to 5–10% for lifestyle modification. Tirzepatide induces mean losses as great as 20.9%. Both medications reduce energy intake by markedly enhancing satiation and decreasing hunger, and they appear to lessen the need for traditional cognitive and behavioral strategies (e.g., monitoring food intake) to achieve calorie restriction. Little, however, is known about whether patients who lose weight with these AOMs adopt healthy diet and activity patterns needed to optimize body composition, cardiometabolic health, and quality of life. Summary: When used with the new AOMs, the focus of lifestyle modification is likely to change from inducing weight loss (through calorie restriction) to facilitating patients’ adoption of dietary and activity patterns that will promote optimal changes in body composition and overall health.

Overview

CoChat Summary

TL;DR

This review argues that with second-generation anti-obesity medications (AOMs), lifestyle modification’s focus shifts from inducing weight loss through calorie restriction to helping patients adopt healthy diet and activity patterns for optimal body composition and overall health. It summarizes semaglutide and tirzepatide efficacy and identifies major knowledge gaps in diet quality, physical activity, body composition, and psychosocial outcomes.

Key findings

  • Semaglutide 2.4 mg reduces baseline body weight by approximately 15% at 68 weeks, and tirzepatide induces mean losses as great as 20.9%, compared with 5–10% for lifestyle modification alone. In STEP 1, semaglutide produced a mean 14.9% loss versus 2.4% for placebo; in SURMOUNT-1, tirzepatide 15 mg produced 20.9% versus 3.1% for placebo.
  • Adding intensive lifestyle modification to semaglutide did not clearly increase long-term weight loss: STEP 3 found 16.0% loss with semaglutide plus intensive behavioral therapy and meal replacements versus 5.7% with placebo, only about 1.1 percentage points more than STEP 1’s less intensive counseling. In SURMOUNT-3, after a 12-week intensive lifestyle lead-in (6.9% loss), tirzepatide added 18.4% from randomization, for a cumulative 24.3% reduction versus 4.5% for placebo.
  • Weight regain after discontinuation is substantial: in a STEP 1 extension subset, participants who lost a mean 17.3% at 68 weeks regained an average 11.6 percentage points (about two-thirds) one year after stopping medication; in STEP 4, participants switched to placebo regained 4.9 percentage points, while those continuing semaglutide lost an additional 6.8%.
  • Safety findings include gastrointestinal adverse events that were typically mild to moderate; discontinuation due to adverse events was approximately 6–7% with semaglutide 2.4 mg or tirzepatide 10–15 mg versus 2.5–3% for placebo. Semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo in persons with overweight/obesity and a history of cardiovascular disease but not type 2 diabetes.

Methods

  • Narrative review examining lifestyle modification for obesity management alongside second-generation AOMs, principally semaglutide 2.4 mg and tirzepatide, including mechanisms, efficacy, safety, and clinical considerations.
  • Evidence base includes published phase 3 STEP and SURMOUNT trials, other randomized trials and guidelines, and the authors’ clinical observations; a summary table reports end-of-treatment changes in seven STEP trials and three SURMOUNT trials.
  • Main analysis is a qualitative synthesis and interpretation; no systematic search, meta-analysis, or primary data collection is reported.

Limitations

  • Stated: little is known about whether patients who lose weight with these AOMs adopt healthy diet and activity patterns; no results have been published on baseline dietary intake, macronutrient changes, meal/snack timing, or problem eating, and few data exist on physical activity or cardiorespiratory fitness.
  • Stated: body composition findings require verification—STEP 1 supplementary data suggested roughly 40% of weight loss came from lean mass, while SURMOUNT-1 suggested approximately 25%, and older-participant estimates are limited by small numbers; psychosocial outcomes including mood and suicidal ideation have not been fully reported.
  • Evident: as a narrative review, it does not systematically appraise or quantitatively pool evidence, and many recommendations are based on existing guidelines and clinical observations rather than randomized trials, as the authors acknowledge.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s13679-023-00534-z

Cites

114 of 114 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Percentage of participants who achieved categorical losses ≥ 5%, ≥ 10%, ≥ 15%, and ≥ 20% of baseline body weight with intensive lifestyle modification alone as compared with semaglutide and tirzepatide (combined with approximately monthly, brief lifestyle counseling) (NR, not reported)
Fig. 1 Percentage of participants who achieved categorical losses ≥ 5%, ≥ 10%, ≥ 15%, and ≥ 20% of baseline body weight with intensive lifestyle modification alone as compared with semaglutide and tirzepatide (combined with approximately monthly, brief lifestyle counseling) (NR, not reported)CC BY · PubMed Central

Verification

Claims the paper makes

12 Valid · 3 Not valid · 103 Not checked · 29 Own results and interpretations

84 more claims · 7 with their cited sources checked

Create a free account to see all 147 claims and to verify the 127 references still open.

See all claims — free account
  • It may state two separate claims as one. 46
  • Probably not a substantial claim. 15

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 117 references

Research works printed but not linked: 5

  1. Jensen MD, Ryan DH, Donato KA, Apovian CM, Ard JD, Comuzzie AG, et al. Guidelines (2013) for managing overweight and obesity in adults. Obesity. 2014;22(S2):S1–410.
  2. Guyenet SJ. The hungry brain: outsmarting the instincts that make us overeat. New York: Flatiron Books; 2017.
  3. U.S. Department of Agriculture and U.S. Department of Health and Human Services. Dietary guidelines for Americans, 2020–2025. 9th Edition. December 2020. Available at: DietaryGuidelines.gov.
  4. Patel JJ, Mundi MS, Martindale RG, Hurt RT. Obesity. In: Mueller CM, editor. The ASPEN adult nutrition core curriculum. 3rd ed. Silver Spring, MD: American Society for Parenteral and Enteral Nutrition; 2017. p. 1028–58.
  5. Sogg S, Gorman MJ. Interpersonal changes and challenges after weight-loss surgery. Prim Psychiatry. 2008;15(8):61–6.

Cited by

See all 129

Metadata

Authors
Wadden, T. A., Chao, A. M., Moore, M., Tronieri, J. S., Gilden, A., Amaro, A., Leonard, S., & Jakicic, J. M.
Affiliations
  • University of Pennsylvania (US)
  • Johns Hopkins University (US)
  • University of Colorado Anschutz (US)
  • University of Kansas Medical Center (US)
Corresponding author
Wadden, Thomas A.
Venue
Current Obesity Reports
Published
2023-12-02
Volume
12
Issue
4
Pages
453-473
ISSN
2162-4968 (ISSN-L)
OpenAlex
W4389267144
Cited by
129
References
117
Citations by year
2026: 30 · 2025: 52 · 2024: 47
FWCI
4.69
Type
journal article
Language
en
Open access
Licence
Locations
  • Current Obesity Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
lifestyle modification, anti-obesity drugs, obesity treatment, semaglutide, tirzepatide, weight loss, satiety, hunger, caloric restriction, dietary habits, physical activity, body composition, cardiometabolic health, quality of life
MeSH terms
Body Weight, Humans, Life Style, Obesity, Quality of Life, Exercise, Anti-Obesity Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities. https://app.cochat.ai/papers/10.1007/s13679-023-00534-z
The paper
Wadden, T. A., Chao, A. M., Moore, M., Tronieri, J. S., Gilden, A., Amaro, A., Leonard, S., & Jakicic, J. M. (2023). The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities. Current Obesity Reports. https://doi.org/10.1007/s13679-023-00534-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.